

**Official Title:** Aerobic Exercise to Improve Mobility in Multiple Sclerosis: Optimizing Design and Execution for a Full-scale Multimodal Remyelination Clinical Trial

**NCT Number:** NCT04539002

**Date:** June 16, 2026

**Manuscript Citation:**

Wooliscroft L, McCoy S, Hildebrand A, Rooney W, Oken BS, Spain RI, Kuehl KS, Bourdette D, Cameron M. Protocol for an exploratory, randomised, single-blind clinical trial of aerobic exercise to promote remyelination in multiple sclerosis. *BMJ Open*. 2023 Jan 3;13(1):e061539. doi: 10.1136/bmjopen-2022-061539. PMID: 36596632; PMCID: PMC9814998.

## INTRODUCTION:

Multiple sclerosis (MS) is the most common non-traumatic cause of neurologic disability in young adults, affecting around 2.8 million people worldwide.<sup>1</sup> In MS, there is intermittent, focal inflammation that leads to demyelination and axonal injury, and ultimately results in disability.<sup>2</sup> Remyelination, however, improves conduction velocity and also provides neuroprotection across the axon; therefore, remyelination has the potential to be an effective long-term strategy to both improve and protect against future disability in people with MS (pwMS).<sup>3 4</sup>

Numerous clinical trials demonstrate that aerobic exercise can improve physical fitness, fatigue, depression and walking mobility,<sup>5 6</sup> and may also reduce the rate of relapse and disease progression in MS.<sup>7-9</sup> Yet, the mechanisms underlying the effects of exercise/physical activity remains a high priority question for wellness research in MS.<sup>10</sup>

In pre-clinical models of MS, aerobic exercise promotes remyelination, both alone and synergistically with pharmacotherapy. In a lysolecithin-induced demyelination study in mice, aerobic exercise was associated with remyelination of 84% of demyelinated axons compared to 51% of axons that remyelinated spontaneously without exercise. The anti-histamine clemastine also promoted remyelination, resulting in 87% axonal remyelination, but adding aerobic exercise to clemastine was even more effective, resulting in 98% axonal remyelination. Additionally, the myelin formed after exercise alone or after exercise with clemastine was thicker than the myelin formed in the mice that did not exercise, supporting that exercise promoted not only more complete, but also more robust remyelination.<sup>11</sup> Aerobic exercise may promote remyelination through various mechanisms including inhibition of auto-immune T-cell and blood brain barrier disruption, optimization of the microenvironment by increased removal of myelin debris, increased oligodendrocyte precursor cell proliferation, increased local neurotrophic factors, and activation of pathways that increase myelin thickness.<sup>11-17</sup> To our knowledge, no clinical trials of aerobic exercise have explored remyelination as the primary outcome in pwMS.

Remyelination clinical trials also require real-world treatment biomarkers that are reliable, valid, reproducible, affordable, and correlate to clinically meaningful outcomes. SSEP latencies from the upper and lower extremities meet many of these requirements as they are reliable, estimate demyelination,<sup>18</sup> and are suitable for multi-center trials.<sup>19</sup> SSEPs are also available for commercial use, so this outcome could be used clinically by MS providers to follow treatment response to remyelinating medications. Motor evoked potentials (MEPs) are also promising potential remyelination biomarkers, but MEPs are dependent on participant arousal and voluntary contraction can lead to intra-individual variability and confound this measure.<sup>20-22</sup> While studies have correlated SSEP latencies to imbalance and fall frequency in pwMS, this will be the first study to examine the associations between SSEP latencies and a panel of mobility metrics in pwMS to inform clinical outcomes for future remyelination clinical trials in pwMS.<sup>23 24</sup>

We will conduct a randomized, single-blind, parallel group, exploratory clinical trial of aerobic stationary cycling compared to an MS education control group in sedentary pwMS. The purpose of this study is to explore the relationship between demyelination,

as measured by SSEP, and clinical measures of mobility in pwMS to explore potential clinical outcomes in future remyelination trials (part 1) and, to explore if aerobic exercise improves mobility and promotes remyelination as measured by functional (somatosensory evoked potentials, SSEP) and structural (myelin water fraction, MWF) measures (part 2). The central hypotheses of this study are that 1) greater spinal cord demyelination (indicated by longer SSEP latency) will be associated with increased motor disability in pwMS, and 2) the aerobic exercise group will demonstrate decreased SSEP latency, increased MWF and clinical improvement compared to an educational control group. This trial will inform the feasibility, clinical outcome measures, design and sample size for a fully powered clinical trial of aerobic exercise for remyelination in pwMS.

## **METHODS AND ANALYSIS:**

### **Study Design**

This study includes two parts. Part 1 is a baseline assessment to explore the relationship between demyelination, as measured by SSEP, and mobility in pwMS. Part 2 is a randomized controlled trial of an aerobic exercise intervention in those who have sensory demyelination at baseline, based on SSEP. Sixty participants will enter part 1 and undergo baseline testing, including SSEPs, mobility outcomes and patient-reported outcomes (PROs). The clinical outcome with the strongest correlation with SSEP latency in part 1 of the study will become the primary clinical outcome to measure remyelination in part 2 of the clinical trial. The first 44 participants with a qualifying lower extremity SSEP z-score will enter part 2 and be randomly allocated to an aerobic cycling intervention with graded supervision (MSCYCLE) or an education control group (MS Take Control, MSTC) [15] (Figure 1). Randomization to MSCYCLE and MSTC will be performed by an unblinded research assistant (RA) in a 1:1 ratio using a random number generator in blocks of four. All participants in part 2 will undergo repeat testing (SSEPs, mobility outcomes, and PROs) at 12 and 24 weeks by study staff blinded to group assignment. A subset of clinical trial participants (11 active and 11 controls) will also be invited to undergo a brain MRI with MWF at baseline and 24 weeks. The first participant was enrolled April 2021. We anticipate that recruitment will be complete by January 2024 and the last participant will exit the trial by July 2024.

### **Participants**

#### **Inclusion criteria**

Participants are included in the study if they meet the following criteria: 1) diagnosis of MS based on the 2017 McDonald criteria, 2) aged between 18 and 64 years (in response to Institutional Review Board feedback as those aged 65 years and above were considered to be at high risk of severe COVID-19), and 3) have access to the internet and a device that can access virtual visits.<sup>25</sup> The first 44 participants with a height-adjusted lower extremity SSEP latency z-score  $\geq 2$  or inter-side difference in z-score  $\geq 2$  for P40 will advance to part 2.

#### **Exclusion criteria**

Participants will be excluded from the study if they: 1) have medical or biophysical conditions that prohibit exercise, 2) already engage in  $>30$  minutes/week of moderate or vigorous aerobic exercise, 3) have a clinically confirmed MS relapse in the past three

months or change in their MS disease modifying therapy (DMT) in the last six months, 4) are pregnant or are planning to become pregnant, 5) received steroids for MS relapse in the last 30 days, 6) have a known history of severe spinal canal stenosis (which would impact SSEPs), and 7) use 4-aminopyridine or dalfampridine (medications which can temporarily alter SSEP) and unwilling to discontinue it for two days prior to each SSEP testing session.

### Recruitment

Patients with MS will be recruited from National MS Society and the Oregon Health & Science University (OHSU) MS Clinic, through OHSU MyChart recruitment invitations, and the OHSU MS Research Recruitment Repository with IRB-approved flyers. PwMS identified as trial candidates will be screened for meeting the inclusion and exclusion criteria including an Activity Readiness Questionnaire (PAR-Q) to determine if the participant can safely commence an exercise routine.<sup>26</sup> If the patient answers “YES” to any of the seven questions in this survey, we will consult with their doctor to determine if they are safe to engage in physical activity. If physician permission is not obtained, the patient will be excluded. Those interested in and determined safe for participation will be provided with the Informed Consent Form (ICF) by study staff to review prior to signing the form at their baseline visit with study staff (See Supplemental Material 1).

### Sample size calculation

Part 1 of the study will explore the relationship of demyelination with mobility in pwMS. Based on prior studies associating transformed SSEP z-scores and the expanded disability status scale ( $\rho=0.81$ ,  $p<0.001$ ) in pwMS,  $n=60$  participants would have 88% power to detect a correlation  $\rho=0.40$  ( $\alpha = 0.05$ ). All power analyses were computed using Power And Sample Size (PASS) software (version 15). For part 2 of the study (to explore if aerobic exercise improves mobility and promotes remyelination), we assume the effect size of z-transformed evoked potential values between baseline and 24 weeks is 0.54 in pwMS based on prior studies.<sup>27</sup> Assuming a 20% drop out rate, enrolling 44 participants in the clinical trial would achieve the necessary final sample size of 36 participants, or 18 per group. This will give us >80% power to detect a 50% effect size ( $\alpha=0.05$ ). Our sample size is similar to prior remyelination clinical trials of the pharmacotherapies clemastine and bexarotene in MS using visual evoked potentials (VEP), a similar functional myelination biomarker of the visual system.<sup>28 29</sup> As this is the first clinical trial of exercise to use SSEP to assess for remyelination, it is unknown if the study intervention, different evoked potential modality, or other factors may impact the required sample size.

To our knowledge, this study is the first clinical trial in MS to use quantitative T<sub>1</sub> MWF as a biomarker of structural remyelination and therefore a well-informed power analysis cannot be performed. However, 11 per group is similar to other studies that have demonstrated changes in white matter integrity in pwMS after rehabilitative interventions.<sup>30 31</sup> If additional funding is obtained, the sample size of the MRI subset may be increased.

### Interventions

### Aerobic exercise group (MSCYCLE)

The active intervention, MSCYCLE, is a thrice weekly, home-based, stationary aerobic cycling intervention conducted over 24 weeks with virtual graded supervision by trained study personnel (hereto called the “trainer”) who will be blinded to the study outcomes. The trainer will provide supervision and collect study data (e.g. minutes in the target HR range, report injuries/adverse events) via a video link.

Before starting the intervention, participants will undergo a  $\text{VO}_2$  max test to determine their  $\text{HR}_{\text{peak}}$  from which to calculate their target HR during the aerobic exercise intervention; the continuous exercise intervention target HR will be 70-80% of  $\text{HR}_{\text{peak}}$ .

Participants will be provided with a recumbent cycle ergometer and a chest strap to monitor their HR. The HR monitor will be linked to a smartphone app which will display their HR during the session and will also record minutes spent in their target HR zone. Participants will also be given an *Aerobic Training Guide* which will review study exercise procedures, injury prevention, and includes a training log.

The MSCYCLE sessions will be conducted with graded virtual supervision by a trainer, progressing from three supervised sessions per week during Weeks 1-4, two supervised and one unsupervised session during Weeks 5-8, to one supervised and two unsupervised sessions per week during Week 9-24. The trainer will work with the participant to increase the heart rate range, as tolerated, on the following schedule: Week 1: 50-60%  $\text{HR}_{\text{peak}}$ ; Week 2: 55-65%  $\text{HR}_{\text{peak}}$ ; Week 3: 60-70%  $\text{HR}_{\text{peak}}$ ; Week 4: 65+%  $\text{HR}_{\text{peak}}$ ; Weeks 5-24 70-80%  $\text{HR}_{\text{peak}}$ .

During the supervised sessions, the trainer and participant will have a scheduled video visit to conduct the exercise intervention. The sessions will include a 5-minute warm-up period, a 30-minute continuous exercise period at their target HR range, followed by a 5-minute cool down period. At the end of the exercise session, the trainer (or the participant if the session is unsupervised) will record the number of minutes during the 30-minute active period that the participant was able to maintain their target HR. The exercise sessions will be modified as needed to accommodate injury or other changes in medical status, or discontinued if the participant is no longer able to exercise safely.

### Control group (MS Take Control, MSTC)

The control intervention, MS Take Control (MSTC), is a monthly, virtual group 60-minute class with 1-9 participants led by a trained facilitator, conducted on a secure virtual platform. We have used this intervention as a control in other studies.<sup>32</sup>

For MSTC, participants will be given informational materials at the time of randomization and be instructed to read one of the following National MS Society pamphlets before each of six monthly sessions: *Driving with MS*, *Managing Cognitive Problems in MS*, *Taming Stress*, *Clear Thinking About Alternative Therapies*, *Urinary Dysfunction and MS* and *Vitamins, Minerals and Herbs in MS: An Introduction*. These topics were chosen as they are of interest to pwMS and the pamphlets provide high quality information produced specifically for pwMS. One pamphlet will be reviewed by the group during each 60-minute session.

Participants in both MSCYCLE and MSTC will be instructed to maintain their current activity levels outside of the sessions during the trial, but are permitted to participate in physical or occupational therapy.

## Outcomes

All outcomes will be conducted and interpreted by study staff blinded to group allocation (Table 1).

| Study Visit #                                                   | #1              | #2 | Intervention                                                                   |                                                                          | #3             | Intervention                                                                   |                                                                          | #4             | #5 |
|-----------------------------------------------------------------|-----------------|----|--------------------------------------------------------------------------------|--------------------------------------------------------------------------|----------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------|----------------|----|
|                                                                 | <i>Baseline</i> |    |                                                                                |                                                                          | <i>Week 12</i> |                                                                                |                                                                          | <i>Week 24</i> |    |
| <b>Consent</b>                                                  | X               |    | <b>MSCYCLE</b><br><br>Stationary aerobic cycling x3/wk with graded supervision | <b>MS: Take Control (MSTC)</b><br><br>Monthly MS-education control group |                | <b>MSCYCLE</b><br><br>Stationary aerobic cycling x3/wk with graded supervision | <b>MS: Take Control (MSTC)</b><br><br>Monthly MS-education control group |                |    |
| <b>Medical and MS history</b>                                   | X               | X  |                                                                                |                                                                          | X              |                                                                                |                                                                          | X              | X  |
| <b>Patient Derived Disease Steps</b>                            | X               |    |                                                                                |                                                                          |                |                                                                                |                                                                          |                |    |
| <b>Inclusion/exclusion &amp; review adverse events</b>          | X               |    |                                                                                |                                                                          | X              |                                                                                |                                                                          | X              |    |
| <b>Biometric data</b>                                           |                 | X  |                                                                                |                                                                          |                |                                                                                |                                                                          |                | X  |
| <b>7-Site Skinfold Testing</b>                                  |                 | X  |                                                                                |                                                                          |                |                                                                                |                                                                          |                | X  |
| <b>VO<sub>2</sub> max</b>                                       |                 | X  |                                                                                |                                                                          |                |                                                                                |                                                                          |                | X  |
| <b>Strength testing</b>                                         | X               |    |                                                                                |                                                                          | X              |                                                                                |                                                                          | X              |    |
| <b>Somatosensory Evoked Potential</b>                           | X               |    |                                                                                |                                                                          | X              |                                                                                |                                                                          | X              |    |
| <b>6 Minute Timed Walk*</b>                                     | X               |    |                                                                                |                                                                          | X              |                                                                                |                                                                          | X              |    |
| <b>Timed Up and Go*</b>                                         | X               |    |                                                                                |                                                                          | X              |                                                                                |                                                                          | X              |    |
| <b>Timed 25 Foot Walk</b>                                       | X               |    |                                                                                |                                                                          | X              |                                                                                |                                                                          | X              |    |
| <b>9-Hole Peg Test</b>                                          | X               |    |                                                                                |                                                                          | X              |                                                                                |                                                                          | X              |    |
| <b>Postural sway*</b>                                           | X               |    |                                                                                |                                                                          | X              |                                                                                |                                                                          | X              |    |
| <b>Retrospective 30 day fall frequency</b>                      | X               |    |                                                                                |                                                                          | X              |                                                                                |                                                                          | X              |    |
| <b>Symbol Digit Modalities Test</b>                             | X               |    |                                                                                |                                                                          | X              |                                                                                |                                                                          | X              |    |
| <b>International Physical Activity Questionnaire-Short Form</b> | X               |    |                                                                                |                                                                          | X              |                                                                                |                                                                          | X              |    |
| <b>Modified Fatigue Impact Scale</b>                            | X               |    |                                                                                |                                                                          | X              |                                                                                |                                                                          | X              |    |
| <b>Pain Effects Scale</b>                                       | X               |    |                                                                                |                                                                          | X              |                                                                                |                                                                          | X              |    |
| <b>Neuro-QOL Lower Extremity Function</b>                       | X               |    |                                                                                |                                                                          | X              |                                                                                |                                                                          | X              |    |
| <b>Neuro-QOL Upper Extremity Function</b>                       | X               |    |                                                                                |                                                                          | X              |                                                                                |                                                                          | X              |    |
| <b>Neuro-QOL Depression</b>                                     | X               |    |                                                                                |                                                                          | X              |                                                                                |                                                                          | X              |    |
| <b>Neuro-QOL Sleep Disturbance</b>                              | X               |    |                                                                                |                                                                          | X              |                                                                                |                                                                          | X              |    |
| <b>PROMIS Self-Efficacy questionnaire</b>                       | X               |    |                                                                                |                                                                          | X              |                                                                                |                                                                          | X              |    |
| <b>Blood draw</b>                                               | X               | X  |                                                                                |                                                                          | X              |                                                                                |                                                                          | X              |    |

|                                       |  |   |  |  |  |  |  |   |
|---------------------------------------|--|---|--|--|--|--|--|---|
| MRI for Myelin Water Fraction (MWF)** |  | X |  |  |  |  |  | X |
| Exit survey                           |  |   |  |  |  |  |  | X |

Table 1. Study Activities; \*: performed with body-worn sensors; \*\*: performed on a subset of trial participants (n=22)

#### Primary Outcomes

##### *Somatosensory Evoked Potential (SSEP)*

SSEP will be performed at baseline, and at 12- and 24-weeks to assess remyelination (Cadwell Elite, Kennewick, WA). SSEP will be recorded after median nerve and posterior nerve electrical stimulation starting with a square pulse of 0.2 ms duration at a rate of 3.11 Hz at 2 mA above motor threshold. The averages of two or more subsequent runs (at least 2x500 pulses) will be inspected for reproducibility and the mean will be used for analysis. For the upper extremities, active surface electrodes will be placed at C3'/C4' contralateral to stimulation (reference: Fz) to obtain N20. For the lower extremities, active surface electrodes will be placed at Cz (reference: Fz) to obtain P40. Recordings will follow the recommendations of the American Clinical Neurophysiology Society.<sup>33</sup> Prolonged latencies of N20 or P40 reflect demyelination within the upper and lower extremity sensory pathways, respectively.<sup>20</sup> SSEP latency z-scores for each limb will be calculated using previously established normative values.<sup>34</sup>

##### *Mobility and Disability Outcomes*

Mobility tests will be conducted at baseline, 12- and 24-weeks. Exercise endurance will be evaluated with the 6-Minute Timed Walk (6MTW).<sup>35</sup> Participants will be asked to walk for six minutes and the total distance will be recorded. Walking mobility will be measured with the Timed Up and Go (TUG).<sup>36</sup> Participants will be asked to stand up from a chair, walk 7 meters, turn, return to the chair, turn and sit down. The average of two timed tests will be recorded. Walking speed will be measured by the Timed 25-Foot Walk (T25FW).<sup>37</sup> To estimate fall frequency, participants will be asked how many falls they have sustained in the prior 30 days. Upper extremity mobility will be measured with the 9 Hole Peg Test (9HPT).<sup>37</sup> During this test the time for participants to place nine pegs into a platform with holes and then take them out again will be measured. MS disability will be measured with the MS Functional Composite (MSFC), a three-part, standardized, quantitative, assessment instrument in MS clinical trials measuring cognition, leg function and arm/hand function and will be calculated using the T25FW, 9HPT and Symbol Digit Modalities Test (SDMT, described in *Cognitive Function* below).<sup>37 38</sup>

Participants will perform the 6MTW and TUG wearing wireless, synchronized inertial sensors on both wrists and ankles as well as on the torso at lumbar vertebra level 5 and chest (superior sternum level).<sup>39</sup> These inertial sensors record 3-D linear acceleration and angular velocities. Participants will also be asked to stand quietly with their hands on hips and their eyes open and closed for 30 seconds each with the sensors on to measure postural sway. These body worn sensors provide robust and quantitative measurements of multiple gait parameters that are reliable in pwMS<sup>39</sup> and are more sensitive than the T25FW for gait dysfunction in early MS.<sup>40</sup> These metrics also

correlate strongly with fall frequency<sup>41</sup> and were successfully employed in our group's previous clinical trial of lipoic acid<sup>42</sup>.

Of the aforementioned mobility outcomes (i.e. 6MTW, TUG, T25FW, MSFC), the one with the strongest correlation with SSEP latency in part 1 of the study will become the primary clinical outcome to measure remyelination in part 2 of this clinical trial.

## Secondary Outcomes

### *Aerobic Fitness and Biometrics*

Aerobic fitness will be measured by maximal oxygen consumption (VO<sub>2</sub> max) at baseline and after the 24-week active or control intervention using an electrocardiogram-monitored, maximal, graded exercise test on a cycle ergometer (Ergoline Via Sprint 150P) and an open-circuit spirometry system (Medgraphics Ultima CardiO2). The initial work rate will be 25 W, increasing by 25 W every three minutes until volitional fatigue and will be followed by a cool-down period, consistent with American College of Sports Medicine guidelines for VO<sub>2</sub> max testing for pwMS.<sup>43</sup> HR and Rated Perceived Exertion (RPE) will be obtained every three minutes. VO<sub>2</sub> max HR will be determined when two of four criteria are met: (1) VO<sub>2</sub> plateaus with increasing work rate; (2) respiratory exchange ratio  $\geq 1.10$ ; (3) peak HR is within 10 beats/min of age-predicted maximum (i.e.,  $\sim 1$  SD); or (4) peak RPE  $> 7$  (0-10 scale).<sup>44</sup> VO<sub>2</sub> max will be used to both to determine the target HR for MSCYCLE participants and to assess the change in aerobic fitness from before to after the interventions.

Body composition will be measured by 7-site skinfold testing using a validated algorithm (Harpender Skinfold Caliper, FG1056; BodyTracker Software) at baseline and 24 weeks. Strength will be measured at baseline, 12 and 24 weeks; strength of the quadriceps and hamstrings will be measured by a hand-held dynamometer (Microfet2, Hogan Health, Ogden, UT). Hand grip strength will also be measured (Jamar Hydraulic Hand Dynamometer).

### *Cognitive Function*

Cognitive function will be measured at baseline, 12- and 24-weeks using the Symbol Digit Modalities Test (SDMT), a valid and reliable measure of processing speed and attention in pwMS.<sup>45</sup> During this test, participants are given 90 seconds to match symbols with numbers and the examiner records the total number correct.

### *Patient Reported Outcomes*

We will measure several PROs at baseline, 12- and 24-weeks to determine if relevant MS symptoms are modified by the interventions. To measure fatigue, we will use the Modified Fatigue Impact Scale (MFIS),<sup>46</sup> a multidimensional questionnaire of fatigue developed for pwMS. To assess pain, we will use the Pain Effects Scale (PES),<sup>47</sup> a validated assessment of the ways in which pain impacts pwMS. To measure physical activity levels, we will use the International Physical Activity Questionnaire Short Form (IPAQ-SF), a validated measurement of physical activity and intensity in adults.<sup>48</sup> To measure health-related quality of life (QOL), we will use computerized adaptive test versions of Neuro-QOL questionnaires of Upper Extremity Function, Lower Extremity

Function, Depression, Sleep Disturbance and the Patient-Reported Outcomes Measurement (PROMIS) Self-Efficacy questionnaire. The PROMIS and Neuro-QOL tools were developed by the National Institutes of Health to assess QOL within and across various general and neurologic conditions.<sup>49</sup>

### *Brain Imaging*

A subset of 22 participants (11 active and 11 control group) will undergo an optional MRI at baseline and 24-weeks as an exploratory outcome measure of structural remyelination of the brain. Whole brain MPRAGE images will be acquired on a 7T MAGNETOM system (Siemens, Erlangen, Germany) using a 24-channel array RF coil (Nova Medical, Wilmington, MA) for co-registration and planning purposes (TI/TE/TR/ $\alpha$ /data matrix/res = 1.05 s/3.1 ms/2.2 s/7°/320x320x240/0.7 mm isotropic). A highly sampled inversion recovery (IR) technique – progressively unsaturated relaxation during perturbed recovery from inversion (PURR) sequence with 32 inversion time points will be implemented to acquire 5 mm thick slices (TI/TE/TR/ $\alpha$ /data matrix/res = 0.017 8.0 s/7 ms/14.0 s/5°/128x128; (2 mm in-plane) ). We will segment white matter structures (the corpus callosum and bilateral internal capsules) and MS lesions superior to the tentorium cerebelli. A multi-exponential fitting procedure will be used on a voxel-wise basis to decompose IR recovery curves into short and long T components. The short T<sub>1</sub> component will be assigned to myelin associated water, and its amplitude will be used to calculate MWF. Tissue water content will be quantified and used to correct MWF. No contrast agent will be administered.

### *Blood Sample Biobanking*

We will obtain 30 cc blood samples at four timepoints: the initial visit, the VO<sub>2</sub> max visit before starting the clinical trial, and 12- and 24-weeks. We are not aware of any accepted remyelination biomarkers in the blood, at present. Serum and platelet-free plasma samples will be stored for analysis of any future remyelination biomarkers.

### *Other Outcomes*

Patient Determined Disease Steps (PDDS) will be assessed at baseline to describe the sample. The PDDS is a patient-reported outcome of disability in MS and has nine ordinal levels ranging between 0 (normal) and 8 (bedridden).<sup>50</sup> Medical and MS history will be obtained at each study visit and the Activity Readiness Questionnaire (PAR-Q) will be performed at baseline and 12 weeks to evaluate for any interval relapses and assure that the participant is still safe to engage in aerobic exercise.<sup>26</sup>

### **Data management and analysis plan**

The original hard copies of study data will be stored in a locked office and de-identified data will be saved on a secure electronic database. De-identified data will be added to an institutional repository after study completion. Data analysis will be overseen by a biostatistician. To determine the relationship between SSEP and measures of clinical disability and mobility, we will perform partial correlations between SSEP P40 and 6MTW, T25FW, MSFC, TUG, postural sway and other body-worn sensor measurements, fall frequency, and lower extremity Neuro-QOL at baseline. We will also perform partial correlations to examine associations between SSEP N20 and upper

extremity dexterity (9HPT) and upper extremity Neuro-QOL. In performing partial correlations, we will control for muscle strength, relevant demographic variables, and disease factors, as needed. As an exploratory outcome, we will also perform partial correlations to examine associations between body structures (VO<sub>2</sub> max, quadricep and hamstring muscle strength, hand grip) and the mobility measures listed above. These analyses will include all participants who provide baseline data.

To determine the safety and feasibility of the cycling intervention, we will track retention and adherence. Adherence will be measured as the number of sessions completed, with successful completion defined as participation in ≥80% of MSCYCLE or MSTC sessions. For MSCYCLE participants, we will perform a subanalysis to examine correlations between average time spent in the target HR zone and improvement in SSEP outcomes and improvement in aerobic fitness as measured by VO<sub>2</sub> max.

To determine whether the cycling intervention is associated with clinical and objective evidence of remyelination, we will perform mixed effect linear regression analyses to model change in clinical measures and SSEP N20 and P40 from baseline to 12- and 24-weeks in active (n=22) and control (n=22) participants. Regression models will include random effects for participant and for limbs within participant. We will also perform a sub-analysis looking at only the worst leg. Determination of the primary clinical outcome for part 2 of the study will be made after analysis of baseline data (see *Mobility and Disability Outcomes*, above), and will be determined before model building begins. Associations between change in SSEP latency and changes in walking-related outcomes will be analyzed by linear regression or analyses of correlation (e.g. Pearson's correlation) on the change scores. To model change in MWF from baseline to 24 weeks, we will perform mixed effects linear regression analyses in active (n=11) and control (n=11) participants of the corpus callosum, bilateral internal capsules, and MS lesions. For all analyses involving multiple testing, an appropriate method of controlling the family-wise error or false detection rate will be chosen prior to beginning the analyses.

### **Data monitoring**

Safety monitoring will involve yearly review of adverse events, dropouts, complaints or breaches of confidentiality. Participants will be encouraged to report any potential problems at any time to the research coordinator or other study staff. We will inquire about adverse events during the assessment visits and MSCYCLE sessions. Adverse events will be judged by the monitor as related, possibly related or unrelated to the study procedures and categorized as mild, moderate or severe. Severe adverse events, unanticipated problems and protocol deviations that are greater than minor will be reported to the OHSU IRB. The OHSU IRB determined that a data monitoring committee was not needed because the study is low risk.

### **Patient and public involvement**

Patients were not involved in the development of the experimental design. Participants in the trial will be invited to provide feedback about their satisfaction with the study and this feedback will be considered in the development of future studies. Results of the trial

will be summarized using lay language in an OHSU MS Center newsletter which will be sent to the study participants.

#### **ETHICS AND DISSEMINATION:**

The proposed study will take place at OHSU in Portland, Oregon, USA, has been approved by the OHSU IRB (reference: 21045), and has been registered on ClinicalTrials.gov (NCT04539002). All participants will provide informed consent prior to study commencement. The results of the study will be presented at scientific conferences and published in peer-reviewed journals, regardless of the findings.

**FIGURE LEGEND:** Figure 1. Participant flow through the study.

**ACKNOWLEDGEMENTS:** The authors would like to thank Anne and Will Foster, Eric and Jan Hoffman, and the Swigert Foundation for their philanthropic donations via the OHSU Foundation to the study; the National MS Society for donating pamphlets for MSTC; Barbara Ochs, R.EEG.T, CNIM and Alex Kanable, BS for the conduct of SSEP and VO<sub>2</sub>max testing, respectively; and our volunteers, Jane Montgomery, PT and Morgan McCoy, BA.

#### **AUTHOR'S CONTRIBUTION:**

LW: study concept and design, study registration, study principal investigator, obtained IRB approval, drafting of the manuscript, and critical revision of the manuscript. SM: drafting of manuscript and critical revision of the manuscript. AH, WR, BO, RS, KK, DB, MC: study concept and design and critical revision of the manuscript.

#### **FUNDING STATEMENT:**

This work was supported by a grant from the National Institutes of Health (National Center for Medical Rehabilitation Research within the National Institute of Child Health and Human Development) to LBW (K23HD101667), OHSU Clinical and Translational Research Center (UL1TR002369), the Myelin Repair Foundation and EMD Serono to LBW and WR (N/A), the Medical Research Foundation of Oregon to LBW (N/A), and the OHSU Foundation to LBW (N/A). This material is the result of work supported with resources and the use of facilities at the Portland VA Health Care System (N/A). Study sponsors and funders will not have a role in study design, collection, management, data analysis, or manuscript composition and submission.

#### **COMPETING INTERESTS:**

None declared.

#### **REFERENCES:**

1. Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. *Multiple Sclerosis Journal* 2020;26(14):1816-21. doi: 10.1177/1352458520970841

2. Thompson AJ, Baranzini SE, Geurts J, et al. Multiple sclerosis. *Lancet* 2018;391(10130):1622-36. doi: 10.1016/S0140-6736(18)30481-1 [published Online First: 2018/03/27]
3. Stangel M, Kuhlmann T, Matthews PM, et al. Achievements and obstacles of remyelinating therapies in multiple sclerosis. *Nat Rev Neurol* 2017;13(12):742-54. doi: 10.1038/nrneurol.2017.139 [published Online First: 2017/11/18]
4. Freund P, Wheeler-Kingshott C, Jackson J, et al. Recovery after spinal cord relapse in multiple sclerosis is predicted by radial diffusivity. *Mult Scler* 2010;16(10):1193-202. doi: 10.1177/1352458510376180 [published Online First: 2010/08/06]
5. Motl RW, Sandroff BM, Kwakkel G, et al. Exercise in patients with multiple sclerosis. *Lancet Neurol* 2017;16(10):848-56. doi: 10.1016/S1474-4422(17)30281-8
6. Dalgas U, Langeskov-Christensen M, Stenager E, et al. Exercise as Medicine in Multiple Sclerosis-Time for a Paradigm Shift: Preventive, Symptomatic, and Disease-Modifying Aspects and Perspectives. *Curr Neurol Neurosci Rep* 2019;19(11):88. doi: 10.1007/s11910-019-1002-3 [published Online First: 20191113]
7. Pilutti LA, Platta ME, Motl RW, et al. The safety of exercise training in multiple sclerosis: a systematic review. *J Neurol Sci* 2014;343(1-2):3-7. doi: 10.1016/j.jns.2014.05.016 [published Online First: 2014/06/02]
8. Langeskov-Christensen M, Grøndahl Hvid L, Nygaard MKE, et al. Efficacy of High-Intensity Aerobic Exercise on Brain MRI Measures in Multiple Sclerosis. *Neurology* 2021;96(2):e203-e13. doi: 10.1212/wnl.00000000000011241 [published Online First: 20201201]
9. Riemenschneider M, Hvid LG, Ringgaard S, et al. Investigating the potential disease-modifying and neuroprotective efficacy of exercise therapy early in the disease course of multiple sclerosis: The Early Multiple Sclerosis Exercise Study (EMSES). *Mult Scler* 2022;13524585221079200. doi: 10.1177/13524585221079200 [published Online First: 20220316]
10. Motl RW, Mowry EM, Ehde DM, et al. Wellness and multiple sclerosis: The National MS Society establishes a Wellness Research Working Group and research priorities. *Mult Scler* 2018;24(3):262-67. doi: 10.1177/1352458516687404 [published Online First: 2017/01/13]
11. Jensen SK, Michaels NJ, Ilyntskyy S, et al. Multimodal Enhancement of Remyelination by Exercise with a Pivotal Role for Oligodendroglial PGC1alpha. *Cell Rep* 2018;24(12):3167-79. doi: 10.1016/j.celrep.2018.08.060
12. Souza PS, Goncalves ED, Pedroso GS, et al. Physical Exercise Attenuates Experimental Autoimmune Encephalomyelitis by Inhibiting Peripheral Immune Response and Blood-Brain Barrier Disruption. *Mol Neurobiol* 2017;54(6):4723-37. doi: 10.1007/s12035-016-0014-0 [published Online First: 2016/07/23]
13. Bernardes D, Oliveira-Lima OC, Silva TV, et al. Differential brain and spinal cord cytokine and BDNF levels in experimental autoimmune encephalomyelitis are modulated by prior and regular exercise. *J Neuroimmunol* 2013;264(1-2):24-34. doi: 10.1016/j.jneuroim.2013.08.014
14. Fabel K, Fabel K, Tam B, et al. VEGF is necessary for exercise-induced adult hippocampal neurogenesis. *Eur J Neurosci* 2003;18(10):2803-12.

15. Trejo JL, Carro E, Torres-Aleman I. Circulating insulin-like growth factor I mediates exercise-induced increases in the number of new neurons in the adult hippocampus. *J Neurosci* 2001;21(5):1628-34.
16. Hlavica M, Delparente A, Good A, et al. Intrathecal insulin-like growth factor 1 but not insulin enhances myelin repair in young and aged rats. *Neurosci Lett* 2017;648:41-46. doi: 10.1016/j.neulet.2017.03.047 [published Online First: 2017/04/02]
17. Pryor WM, Freeman KG, Larson RD, et al. Chronic exercise confers neuroprotection in experimental autoimmune encephalomyelitis. *J Neurosci Res* 2015;93(5):697-706. doi: 10.1002/jnr.23528
18. Hardmeier M, Fuhr P. Multimodal Evoked Potentials as Candidate Prognostic and Response Biomarkers in Clinical Trials of Multiple Sclerosis. *J Clin Neurophysiol* 2021;38(3):171-80. doi: 10.1097/WNP.0000000000000723
19. Hardmeier M, Leocani L, Fuhr P. A new role for evoked potentials in MS? Repurposing evoked potentials as biomarkers for clinical trials in MS. *Mult Scler* 2017;23(10):1309-19. doi: 10.1177/1352458517707265 [published Online First: 2017/05/10]
20. BS Oken TP. Evoked Potentials: Clinical. In: Squire L, ed. *Encyclopedia of Neuroscience*: Oxford: Academic Press 2009:19-28.
21. Di Lazzaro V, Ziemann U, Lemon RN. State of the art: Physiology of transcranial motor cortex stimulation. *Brain Stimul* 2008;1(4):345-62. doi: 10.1016/j.brs.2008.07.004 [published Online First: 20081007]
22. Groppa S, Oliviero A, Eisen A, et al. A practical guide to diagnostic transcranial magnetic stimulation: report of an IFCN committee. *Clin Neurophysiol* 2012;123(5):858-82. doi: 10.1016/j.clinph.2012.01.010 [published Online First: 20120219]
23. Chinnadurai SA, Gandhirajan D, Srinivasan AV, et al. Predicting falls in multiple sclerosis: Do electrophysiological measures have a better predictive accuracy compared to clinical measures? *Mult Scler Relat Disord* 2018;20:199-203. doi: 10.1016/j.msard.2018.01.027 [published Online First: 2018/02/08]
24. Cameron MH, Horak FB, Herndon RR, et al. Imbalance in multiple sclerosis: a result of slowed spinal somatosensory conduction. *Somatosens Mot Res* 2008;25(2):113-22. doi: 10.1080/08990220802131127 [published Online First: 2008/06/24]
25. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurol* 2018;17(2):162-73. doi: 10.1016/S1474-4422(17)30470-2 [published Online First: 2017/12/26]
26. Thomas S, Reading J, Shephard RJ. Revision of the Physical Activity Readiness Questionnaire (PAR-Q). *Can J Sport Sci* 1992;17(4):338-45. [published Online First: 1992/12/01]
27. Schlaeager R, Hardmeier M, D'Souza M, et al. Monitoring multiple sclerosis by multimodal evoked potentials: Numerically versus ordinally scaled scoring systems. *Clin Neurophysiol* 2016;127(3):1864-71. doi: 10.1016/j.clinph.2015.11.041
28. Green AJ, Gelfand JM, Cree BA, et al. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. *Lancet* 2017;390(10111):2481-89. doi: 10.1016/S0140-6736(17)32346-2 [published Online First: 2017/10/17]
29. Brown JWL, Cunniffe NG, Prados F, et al. Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-

- controlled, parallel-group, phase 2a study. *Lancet Neurol* 2021;20(9):709-20. doi: 10.1016/S1474-4422(21)00179-4
30. Ibrahim I, Tintera J, Skoch A, et al. Fractional anisotropy and mean diffusivity in the corpus callosum of patients with multiple sclerosis: the effect of physiotherapy. *Neuroradiology* 2011;53(11):917-26. doi: 10.1007/s00234-011-0879-6 [published Online First: 2011/05/11]
  31. Prosperini L, Fanelli F, Petsas N, et al. Multiple sclerosis: changes in microarchitecture of white matter tracts after training with a video game balance board. *Radiology* 2014;273(2):529-38. doi: 10.1148/radiol.14140168 [published Online First: 2014/08/27]
  32. Hugos CL, Chen Z, Chen Y, et al. A multicenter randomized controlled trial of two group education programs for fatigue in multiple sclerosis: Short- and medium-term benefits. *Mult Scler* 2019;25(2):275-85. doi: 10.1177/1352458517745723 [published Online First: 2017/12/12]
  33. American Clinical Neurophysiology S. Guideline 9D: Guidelines on short-latency somatosensory evoked potentials. *J Clin Neurophysiol* 2006;23(2):168-79. doi: 10.1097/00004691-200604000-00013 [published Online First: 2006/04/14]
  34. Hardmeier M, Jacques F, Albrecht P, et al. Multicentre assessment of motor and sensory evoked potentials in multiple sclerosis: reliability and implications for clinical trials. *Mult Scler J Exp Transl Clin* 2019;5(2):2055217319844796. doi: 10.1177/2055217319844796 [published Online First: 2019/05/10]
  35. Savci S, Inal-Ince D, Arikan H, et al. Six-minute walk distance as a measure of functional exercise capacity in multiple sclerosis. *Disabil Rehabil* 2005;27(22):1365-71. doi: 10.1080/09638280500164479 [published Online First: 2005/12/24]
  36. Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic functional mobility for frail elderly persons. *J Am Geriatr Soc* 1991;39(2):142-8. doi: 10.1111/j.1532-5415.1991.tb01616.x [published Online First: 1991/02/01]
  37. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. *Brain* 1999;122 ( Pt 5):871-82. doi: 10.1093/brain/122.5.871 [published Online First: 1999/06/04]
  38. Drake AS, Weinstock-Guttman B, Morrow SA, et al. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test. *Mult Scler* 2010;16(2):228-37. doi: 10.1177/1352458509354552 [published Online First: 2009/12/24]
  39. Craig JJ, Bruetsch AP, Lynch SG, et al. Instrumented balance and walking assessments in persons with multiple sclerosis show strong test-retest reliability. *J Neuroeng Rehabil* 2017;14(1):43. doi: 10.1186/s12984-017-0251-0 [published Online First: 2017/05/24]
  40. Spain RI, St George RJ, Salarian A, et al. Body-worn motion sensors detect balance and gait deficits in people with multiple sclerosis who have normal walking speed. *Gait Posture* 2012;35(4):573-8. doi: 10.1016/j.gaitpost.2011.11.026 [published Online First: 2012/01/27]
  41. Tajali S, Mehravar M, Negahban H, et al. Impaired local dynamic stability during treadmill walking predicts future falls in patients with multiple sclerosis: A prospective cohort study. *Clin Biomech (Bristol, Avon)* 2019;67:197-201. doi: 10.1016/j.clinbiomech.2019.05.013 [published Online First: 2019/06/25]

42. Loy BD, Fling BW, Horak FB, et al. Effects of lipoic acid on walking performance, gait, and balance in secondary progressive multiple sclerosis. *Complement Ther Med* 2018;41:169-74. doi: 10.1016/j.ctim.2018.09.006 [published Online First: 2018/11/28]
43. Liguori G, Medicine ACoS. ACSM's Guidelines for Exercise Testing and Prescription: Lippincott Williams & Wilkins 2021.
44. Motl RW, Fernhall B. Accurate prediction of cardiorespiratory fitness using cycle ergometry in minimally disabled persons with relapsing-remitting multiple sclerosis. *Arch Phys Med Rehabil* 2012;93(3):490-5. doi: 10.1016/j.apmr.2011.08.025 [published Online First: 2012/01/10]
45. Benedict RH, DeLuca J, Phillips G, et al. Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis. *Mult Scler* 2017;23(5):721-33. doi: 10.1177/1352458517690821 [published Online First: 2017/02/17]
46. Fisk JD, Pontefract A, Ritvo PG, et al. The impact of fatigue on patients with multiple sclerosis. *Can J Neurol Sci* 1994;21(1):9-14. [published Online First: 1994/02/01]
47. Marrie RA, Goldman M. Validity of performance scales for disability assessment in multiple sclerosis. *Mult Scler* 2007;13(9):1176-82. doi: 10.1177/1352458507078388 [published Online First: 2007/07/12]
48. Lee PH, Macfarlane DJ, Lam TH, et al. Validity of the International Physical Activity Questionnaire Short Form (IPAQ-SF): a systematic review. *Int J Behav Nutr Phys Act* 2011;8:115. doi: 10.1186/1479-5868-8-115 [published Online First: 2011/10/25]
49. Cella D, Lai JS, Nowinski CJ, et al. Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology. *Neurology* 2012;78(23):1860-7. doi: 10.1212/WNL.0b013e318258f744 [published Online First: 2012/05/11]
50. Learmonth YC, Motl RW, Sandroff BM, et al. Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. *BMC Neurol* 2013;13:37. doi: 10.1186/1471-2377-13-37 [published Online First: 2013/04/27]